Documentos relacionados

1. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
2. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
3. In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms.
4. Leuconostoc garlicum: an unusual pathogen in the era of vancomycin therapy.
5. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
6. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
7. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii.
8. <i>In Vitro</i> Activity of Sulbactam-Durlobactam against Global Isolates of <i>Acinetobacter baumannii</i>-<i>calcoaceticus</i> Complex Collected from 2016 to 2021.
9. Comparison of the efficacies of three empirically-selected antibiotics for treating Acinetobacter baumannii pulmonary infection: experience from a teaching hospital in China

.
10. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections.